Illana Gozes
Professor of Clinical Biochemistry The Lily and Avraham Gildor Chair for the Investigation of Growth Factors Director
The Adams Super Center for Brain Studies and The Levie- Edersheim-Gitter fMRI Institute; Head
the Dr. Diana andZelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology Sackler Faculty of Medicine Tel Aviv University; Tel Aviv 69978
Israel
Name/email consistency: high
- Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide). Gozes, I. Curr. Pharm. Des. (2011)
- Protection Against Tauopathy by the Drug Candidates NAP (Davunetide) and D-SAL: Biochemical, Cellular and Behavioral Aspects. Shiryaev, N., Pikman, R., Giladi, E., Gozes, I. Curr. Pharm. Des. (2011)
- Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Gozes, I. Peptides (2011)
- Tau pathology and future therapeutics. Gozes, I. Curr. Alzheimer. Res (2010)
- Addressing Alzheimer's Disease Tangles: From NAP to AL-108. Gozes, I., Stewart, A., Morimoto, B., Fox, A., Sutherland, K., Schmeche, D. Current. Alzheimer. Research (2009)
- Addressing Alzheimer's disease tangles: from NAP to AL-108. Gozes, I., Stewart, A., Morimoto, B., Fox, A., Sutherland, K., Schmeche, D. Current. Alzheimer. Research (2009)
- NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). Gozes, I., Divinski, I., Piltzer, I. BMC. Neurosci (2008)
- VIP, from gene to behavior and back: summarizing my 25 years of research. Gozes, I. J. Mol. Neurosci. (2008)
- NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Gozes, I., Divinski, I. Curr. Alzheimer. Res (2007)
- Activity-dependent neuroprotective protein: from gene to drug candidate. Gozes, I. Pharmacol. Ther. (2007)
- Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Gozes, I., Spivak-Pohis, I. Current. Alzheimer. Research (2006)
- The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Gozes, I., Zaltzman, R., Hauser, J., Brenneman, D.E., Shohami, E., Hill, J.M. Current. Alzheimer. Research (2005)
- NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Gozes, I., Morimoto, B.H., Tiong, J., Fox, A., Sutherland, K., Dangoor, D., Holser-Cochav, M., Vered, K., Newton, P., Aisen, P.S., Matsuoka, Y., van Dyck, C.H., Thal, L. CNS. Drug. Rev (2005)
- NAP mechanisms of neuroprotection. Gozes, I., Steingart, R.A., Spier, A.D. J. Mol. Neurosci. (2004)
- Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. Gozes, I., Furman, S. Best Pract. Res. Clin. Endocrinol. Metab. (2004)
- The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. Gozes, I., Divinski, I. J. Alzheimers Dis. (2004)
- VIP and drug design. Gozes, I., Furman, S. Curr. Pharm. Des. (2003)
- Neuroscience collaborations meeting report: the Israel Society for Neuroscience, and the Institute of Neurosciences, Mental Health and Addiction in Canada, first joint meeting, Sunday, Dec. 15, 2002, Eilat, Israel. Gozes, I. J. Mol. Neurosci. (2003)
- From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. Gozes, I., Divinsky, I., Pilzer, I., Fridkin, M., Brenneman, D.E., Spier, A.D. J. Mol. Neurosci. (2003)
- NAP accelerates the performance of normal rats in the water maze. Gozes, I., Alcalay, R., Giladi, E., Pinhasov, A., Furman, S., Brenneman, D.E. J. Mol. Neurosci. (2002)
- Tau as a drug target in Alzheimer's disease. Gozes, I. J. Mol. Neurosci. (2002)
- Neuropeptides: brain messengers of many faces. Gozes, I., Brenneman, D.E., Geppetti, P., Kastin, A.J., Mains, R.E., Moody, T.W., Seroogy, K., Spier, A.D., Zimmermann, M. Trends Neurosci. (2001)
- Neuroprotective peptide drug delivery and development: potential new therapeutics. Gozes, I. Trends Neurosci. (2001)
- A new concept in the pharmacology of neuroprotection. Gozes, I., Brenneman, D.E. J. Mol. Neurosci. (2000)
- Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. Gozes, I., Giladi, E., Pinhasov, A., Bardea, A., Brenneman, D.E. J. Pharmacol. Exp. Ther. (2000)
- A novel VIP responsive gene. Activity dependent neuroprotective protein. Gozes, I., Zamostiano, R., Pinhasov, A., Bassan, M., Giladi, E., Steingart, R.A., Brenneman, D.E. Ann. N. Y. Acad. Sci. (2000)
- Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Gozes, I., Perl, O., Giladi, E., Davidson, A., Ashur-Fabian, O., Rubinraut, S., Fridkin, M. Proc. Natl. Acad. Sci. U.S.A. (1999)
- Pharmaceutical VIP: prospects and problems. Gozes, I., Fridkinb, M., Hill, J.M., Brenneman, D.E. Curr. Med. Chem. (1999)
- A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Gozes, I., Bassan, M., Zamostiano, R., Pinhasov, A., Davidson, A., Giladi, E., Perl, O., Glazner, G.W., Brenneman, D.E. Ann. N. Y. Acad. Sci. (1999)
- Protection against developmental deficiencies by a lipophilic VIP analogue. Gozes, I., Bachar, M., Bardea, A., Davidson, A., Rubinraut, S., Fridkin, M. Neurochem. Res. (1998)
- Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Gozes, I., Perl, O., Zamostiano, R., Rubinraut, S., Fridkin, M., Shochat, L., Lewin, L.M. Ann. N. Y. Acad. Sci. (1998)
- Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Gozes, I., Lilling, G., Davidson, A., Bardea, A., Reshef, A., Glazer, R., Zamostiano, R., Ashur-Fabian, O., Ticher, A., Ashkenazi, I.E., Moody, T.W., Rubinraut, S., Fridkin, M., Brenneman, D.E. Ann. N. Y. Acad. Sci. (1996)